Managing Patients With Insomnia and Comorbid Conditions: Highlights From a SLEEP 2018 CME Symposium on Orexins

Released On
October 19, 2018

Expires On
October 31, 2019

Media Type

Completion Time
45 minutes

Insomnia and comorbid conditions


Scroll to the Bottom of this Information to Begin this Course

This activity is jointly provided by Postgraduate Institute for Medicine ( and MedEdicus LLC.


Supported by an educational grant from Merck & Co., Inc.

Credit Available

  • Physicians - maximum of 0.75 AMA PRA Category 1 Credit
  • Nurses - 0.8 contact hour

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This activity is intended for primary care physicians, nurse practitioners, and physician assistants engaged in the care of patients with insomnia and comorbid conditions.

Program Overview

The desired results of this case-based enduring activity are to cover the treatment and management of insomnia and comorbid conditions.

Educational Objectives

After completing this activity, the participant should be better able to:

  • Incorporate evidence-based approaches to the management of patients with insomnia and comorbid conditions
  • Incorporate effective clinician and patient communications related to insomnia management


Thomas Roth, PhD (Chair)

Sleep Disorders and Research Center
Henry Ford Hospital
Detroit, Michigan

Ruth Benca, MD, PhD

Professor and Chair
Department of Psychiatry and Human Behavior
University of California, Irvine School of Medicine
Irvine, California

Wendy Wright, NP

Wright & Associates Family Healthcare, PLLC
Amherst, New Hampshire
Concord, New Hampshire

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and MedEdicus LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.8 contact hour.

Designated for 0.5 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.

Disclosure of Conflicts of Interest

The Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.


Ruth Benca, MD, PhD

  • Consulting fees (e.g., advisory boards) from Eisai Co, Ltd; Janssen Global Services, LLC; Jazz Pharmaceuticals Inc; Merck & Co., Inc.; and Purdue Pharma LP.
  • Contracted research for Merck & Co., Inc.

Thomas Roth, PhD

  • Consulting fees (e.g., advisory boards) from Actelion Pharmaceuticals Ltd; Avadel Pharmaceuticals, PLC; GlaxoSmithKline; Jazz Pharmaceuticals Inc; Merck & Co., Inc; Novartis Pharmaceuticals; Pfizer Inc; and SEQ.

Wendy Wright, NP

  • Consulting fees (e.g., advisory boards) from Arbor Pharmaceuticals; Merck & Co., Inc; Pfizer Inc; and Sanofi Pasteur SA.
  • Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their Agents (e.g., speakers’ bureaus) from Merck & Co., Inc; Pfizer Inc; and Sanofi Pasteur SA.

Planners and Managers

  • The PIM planners and managers have nothing to disclose.
  • The MedEdicus planners and managers have nothing to disclose.

Fee Information

There is no fee for this educational activity.

Instructions for Obtaining Credit

During the period October 19, 2018, through October 31, 2019, participants must 1) read the learning objectives and disclosures; 2) study the educational activity; and 3) complete the post-test and the evaluation form. To answer the questions, click on your selected choice for each answer then proceed to the next question. We recommend that you print a copy of your answers before you submit them to us. Once completed, click on Submit Post-test at the bottom of the page. Your post-test will automatically be graded. If you successfully complete the post-test (score of 75% or higher), your certificate will be made available immediately. Click on View Certificate and print the certificate for your records. If you receive a score of 74% or less, you will receive a message notifying you that you did not pass the post-test. You may retake the post-test until successful.

Computer System Requirements

This site requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, and Real Networks Real One Player. You can visit the independent (3rd party) site to determine if you have the latest version of your browser.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

This CME/CE activity is copyrighted to MedEdicus LLC ©2018. All rights reserved. 163